The Aviation Medication Transparency Act of 2025 would require the Federal Aviation Administration (FAA) to publish and maintain a public list of medications and treatments that may be safely prescribed to airmen for medical certification. The list must be available within one year of enactment and kept up to date going forward.
The intention is to provide clear, consistently applied guidance for airmen, aviation medical examiners, and aviation employers.
The bill specifies how the list should be built and maintained: it must be comprehensive, user-friendly, and include a Do Not Issue designation; provide a mechanism for clinicians to contact the FAA with questions; and include contextual information about treatment windows on medications and any other clarifications the Administrator deems appropriate. Importantly, the list is to be updated annually, reflecting new medical evidence or policy considerations and incorporating input from key stakeholder groups.
At a Glance
What It Does
The FAA must publish and maintain a publicly accessible list of medications and treatments that may be safely prescribed to airmen for medical certification, within one year of enactment, and update it annually.
Who It Affects
Airmen seeking certification, aviation medical examiners, airlines and aviation employers, and aviation healthcare providers who consult the list for guidance.
Why It Matters
Public access and standardized guidance reduce ambiguity in certification decisions, support safety with up-to-date information, and provide a clear reference for clinicians and employers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill requires the FAA to publish a list of medications and treatments that may be safely used by airmen who are seeking or renewing medical certification. This list must be posted on a public FAA website and kept up to date, with a new edition issued annually.
It must be comprehensive and written so that clinicians and pilots can understand it without specialized legal or medical jargon.
The bill also outlines what the list should contain: a Do Not Issue section, guidance on any necessary periods away from duties needed to stabilize on a medication, and a clear channel for doctors to contact the FAA with questions. In developing the list, the FAA must consult with the Aeromedical Innovation and Modernization Working Group, the air traffic controllers’ representative, the principal airline pilots’ association, and other relevant stakeholders, and it may include other information the Administrator deems appropriate.
The aim is to improve transparency, consistency, and safety in the medical certification process and to keep the list current with evolving medical guidance.
The Five Things You Need to Know
Publication deadline: Not later than one year after enactment, the FAA must publish and maintain a publicly accessible list of medications for airman certification.
Comprehensive and user-friendly: The list must be complete, easy to understand, and posted publicly, with guidance on duty-stabilization periods for medications.
Do Not Issue: The list includes a designated Do Not Issue section to deter certain prescriptions for airmen.
Stakeholder consultation: Drafting includes input from the Aeromedical Innovation and Modernization Working Group, air traffic controllers’ representatives, and the largest pilot bargaining group, among others.
Annual updates: The FAA must update the list annually after initial publication.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short Title
This section designates the act's name as the Aviation Medication Transparency Act of 2025. The title provides a clear reference for policy discussion, oversight, and compliance planning.
List of Approved Medications: publication, contents, and updates
Not later than one year after enactment, the Administrator of the FAA must publish and maintain a list of medications and treatments that may be safely prescribed to airmen for medical certification, and keep it publicly accessible on the FAA website. The list must be comprehensive, user-friendly, and include a Do Not Issue designation, a mechanism for medical providers to contact the FAA with questions, and explanatory information about conditions a medication may treat and why it is allowed or prohibited. It also requires indication of any typical duty-rest period needed to stabilize on a medication and mandates annual updates to reflect new evidence and policy considerations.
This bill is one of many.
Codify tracks hundreds of bills on Transportation across all five countries.
Explore Transportation in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Airmen seeking or renewing medical certification gain a transparent, consistent reference for approved medications and treatment expectations.
- Aviation medical examiners have a standardized resource that reduces ambiguity in certification decisions.
- Airlines and aviation employers benefit from clearer, uniform standards for assessing pilot fitness.
- Pilot associations and bargaining representatives ensure credible input into the medication list and its application.
- Aviation healthcare providers and clinics gain a defined framework for prescribing and advising airmen.
Who Bears the Cost
- The FAA bears ongoing administrative costs to develop, publish, and annually update the list and maintain the public website.
- Medical professionals must review the list and keep their knowledge current, potentially adapting practice patterns.
- Airmen may need to adjust medications or treatment plans to align with the list and its Do Not Issue constraints.
- Airlines and aviation employers may incur policy updates and compliance costs to reflect the standardized guidance.
- The healthcare system may experience short-term increases in queries to FAA for clarification as physicians become familiar with the new resource.
Key Issues
The Core Tension
The central dilemma is balance between transparency and clinical discretion: publishing a definitive, easy-to-use list supports safety and predictability, yet medicine evolves and individual cases require nuance beyond the list, creating a potential gap between policy and practice.
The bill creates a structured approach to medication transparency in aviation medicine, but it also introduces several tensions. On one hand, a comprehensive, publicly accessible list can reduce uncertainty, enhance safety, and promote consistency in medical certification decisions across providers and jurisdictions.
On the other hand, the need for completeness and timely updates may strain FAA resources and could risk over-categorizing medications, which might restrict clinically appropriate treatments for some airmen. The requirement for a Do Not Issue list and the duty-stabilization guidance could influence prescribing choices, potentially leading to unintended barriers to care if clinicians and airmen interpret the guidance too rigidly.
Finally, the success of this framework hinges on effective stakeholder engagement and timely updates to reflect advances in aviation medicine.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.